Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
Public ClinicalTrials.gov record NCT01419184. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Study to Evaluate Comparative Effectiveness, Inpatient Resource Utilization, and Cost of Daptomycin vs. Vancomycin in the Treatment of Patients With Complicated Skin and Skin Structure Infections Due to Suspected or Documented Methicillin-resistant Staphylococcus Aureus (MRSA)
Study identification
- NCT ID
- NCT01419184
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Enrollment
- 250 participants
Conditions and interventions
Conditions
Interventions
- Daptomycin Drug
- Vancomycin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 8, 2011
- Primary completion
- Aug 31, 2012
- Completion
- Oct 4, 2012
- Last update posted
- Sep 4, 2018
2011 – 2012
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Mobile | Alabama | — | — |
| Not listed | Chula Vista | California | — | — |
| Not listed | Escondido | California | — | — |
| Not listed | La Mesa | California | — | — |
| Not listed | Oceanside | California | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Decatur | Georgia | — | — |
| Not listed | Waterloo | Iowa | — | — |
| Not listed | Topeka | Kansas | — | — |
| Not listed | Louisville | Kentucky | — | — |
| Not listed | New Orleans | Louisiana | — | — |
| Not listed | Worcester | Massachusetts | — | — |
| Not listed | Detroit | Michigan | — | — |
| Not listed | Royal Oak | Michigan | — | — |
| Not listed | Minneapolis | Minnesota | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albany | New York | — | — |
| Not listed | East Meadow | New York | — | — |
| Not listed | Mineola | New York | — | — |
| Not listed | The Bronx | New York | — | — |
| Not listed | Winston-Salem | North Carolina | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Toledo | Ohio | — | — |
| Not listed | Rapid City | South Dakota | — | — |
| Not listed | Austin | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01419184, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 4, 2018 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01419184 live on ClinicalTrials.gov.